MyMD Pharmaceuticals, Inc.

As of May 11, 2020, MyMD Pharmaceuticals, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics such as a -57.42% return on equity and an 88% year-to-date decline, especially when compared to its peers.

As of April 28, 2025, MyMD Pharmaceuticals, Inc. shows a mildly bearish trend due to daily moving averages indicating bearish momentum, despite some bullish signals from the weekly MACD and monthly RSI, reflecting mixed indicators and prevailing short-term bearish sentiment.

As of March 2022, the management team of MyMD Pharmaceuticals, Inc. includes Mr. Joshua Silverman as Chairman of the Board, along with Independent Directors Mr. Robert Schroeder and Mr. Bill White.

MyMD Pharmaceuticals, Inc. develops and supplies point-of-care screening and testing products in the Pharmaceuticals & Biotechnology sector. It has a market cap of $2.12 million and reported a net profit loss of $1 million as of March 2025.

As of Jun 18, MyMD Pharmaceuticals, Inc. has a market capitalization of 2.12 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -14.68 million over the latest four quarters. The company's shareholder's funds are 14.72 million, and total assets are 21.42 million.